The latest on prescription digital therapeutics

It’s been a buzzy few years for prescription digital therapeutics, marked by bankruptcies, reimbursement policy changes and AI advancements.

At their best, DTx solutions can offer a more personalized, convenient and cost-effective care experience. But barriers to adoption remain. What are they, and what’s being done about them? Senior Writer Anastassia Gliadkovskaya explores these questions with Joseph Perekupka, CEO of Freespira, and Andy Molnar, SVP of industry affairs for the American Telemedicine Association.

To learn more about the topics in this episode:

• Access to Prescription Digital Therapeutics Act reintroduced in Congress
• How companies use scientifically informed music to impact health outcomes
• CMS puts forward meager offering for digital health in final Medicare physician fee schedule rule
• American Telemedicine Association's lobbying division acquires Digital Therapeutics Alliance

See omnystudio.com/listener for privacy information.